Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multi-Centre Phase II Study Evaluating the Long-Term Safety and Clinical Activity of Neoantigen Reactive T Cells in Patients Who Have Previously Received ATL001 in a Clinical Trial

Next Previous
X
Search
Trial Profile

An Open-Label, Multi-Centre Phase II Study Evaluating the Long-Term Safety and Clinical Activity of Neoantigen Reactive T Cells in Patients Who Have Previously Received ATL001 in a Clinical Trial

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATL 001 (Primary)
  • Indications Malignant melanoma; Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Achilles Therapeutics

    • Most Recent Events

    • 17 Nov 2023 One more primary end-point and a no-drug administration treatment arm is added.
    • 17 Nov 2023 Status changed from not yet recruiting to discontinued because the long-term follow-up of patients is merged to the original (parent) study protocols(Trial ID: ATX-NS-001 / NCT: NCT04032847;Trial ID: ATX-ME-001 / NCT: NCT03997474), and this study is terminated by the Sponsor.
    • 15 Feb 2022 Planned initiation date changed from 1 Jul 2021 to 1 Jun 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top